In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...

周一，Piper Sandler重申对Edgewise ...

周五，渣打银行开始对Edgewise Therapeutics（NASDAQ:EWTX）进行研究覆盖，给予"板块超配"评级，目标价为每股50.00美元，显著高于当前28.13美元的交易价格。根据 InvestingPro ...

BOULDER, Colo., March 11, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise’s product candidates and programs, including sevasemten ...

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference – Company to host an Industry Forum to discuss ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price target of ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten ...